About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
How we work:
-
PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
-
COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
-
BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
How you’ll contribute:
Reporting to the SVP, Translational Medicine, you will lead Translational Medicine efforts for Kymera’s I/I portfolio, including our disclosed oral degrader programs in STAT6 (KT-621), TYK2 (KT-294), and Sanofi-partnered IRAK4 (KT-474).
- KT-621: In preclinical studies, KT-621, Kymera’s first-in-class oral STAT6 degrader, demonstrated full inhibition of the IL-4/IL-13 pathway in all relevant human cell contexts with picomolar potency that was superior to dupilumab, and equivalent or superior efficacy to dupilumab in multiple preclinical efficacy studies.
- KT-294: In preclinical studies, KT-294 demonstrated picomolar to nanomolar potencies across all relevant human cell contexts evaluated, representing what Kymera believes is the only approach to TYK2 targeting that has the potential to recapitulate the human loss-of-function biology of near full pathway inhibition of Type I IFN, IL-12 and IL-23, while also sparing IL-10.
- KT-474: Following completion of Phase 1 and demonstration of target degradation, pathway inhibition, and preliminary activity in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients (results published in Nature Medicine), the program has transitioned to Sanofi which is responsible for conducting randomized, placebo-controlled Phase 2 studies in HS and AD that are ongoing.
You will apply your immunology biology and translational medicine experience to identify and solve challenges and drive efficient decision-making for all translational immunology projects, from assay development to clinical translation of immunology pipeline programs. You will also provide input on other I/I programs, as needed.
- Provide Translational Medicine and Immunology leadership to multiple drug discovery programs in Kymera’s immunology pipeline, driving translational projects from discovery into early and late clinical development.
- Collaborate with key stakeholders to define clear translational trial endpoints.
- Bring a rigorous and efficient science-first philosophy to enable real-time analysis of clinical trial laboratory data.
- Direct efforts at both Contract Research Organizations and in Kymera’s labs, as needed, to support clinical biomarker studies and drive progression within aggressive timelines.
- Enable program success through building external relationships to bring appropriate scientific experts to identify and solve key problems within programs.
- Represent the program team in discussions with management, scientific advisors, and external stakeholders.
- Work with management to ensure progress to goals and flexibly manage priorities in a dynamic scientifically rigorous small company environment.
- Mentor and provide guidance to translational medicine project leads.
What skills and experience you’ll bring:
- PhD, MD/PhD in Immunology or related discipline with a minimum of 15 years of relevant experience in preclinical and clinical immunology, including project leadership experience. Training/experience in clinical laboratory medicine preferred.
- Expertise in the subject area of Immunology, with a track record of translating molecular understanding of disease processes into competitive clinical positioning of projects.
- Proven track record of developing and successfully implementing translational immunology, pharmacodynamic, and patient selection assays in Phase 1 and Phase 2 clinical trials.
- Experience in both large and small company environments is preferred.
- Strong communication skills, including track record of publications, presentations, and key contributions to regulatory documents (e.g. briefing documents, IND, NDA).
- Attention to detail and proven success in handling, analyzing, and presenting experimental and translational data to drive decision making.
- Excellent oral and written communication skills with the ability to manage discussions with a variety of audiences ranging from junior team members to Executive Team.
- Demonstrated capability to collaborate with, lead, influence and inspire team members, stakeholders, and peers.
- Enthusiastic, goal-driven, open-minded, creative and self-aware, with excellent communications, strategic and people-leadership skills.
- Willingness to “roll up your sleeves” and engage at the direct hands-on level to ensure that decisions are implemented and driven to results.
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
